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A B S T R A C T
Objectives: Trypanosoma cruzi reactivation in HIV patients is considered an opportunistic infection,
usually with a fatal outcome. The aim of this study was to describe the epidemiological and clinical
features of T. cruzi infection in HIV patients and to compare these findings between patients with and
without Chagas disease reactivation.
Methods: The medical records of T. cruzi–HIV co-infected patients treated at the Muñiz Infectious
Diseases Hospital from January 2005 to December 2014 were reviewed retrospectively. Epidemiological
and clinical features were assessed and compared between patients with and without Chagas disease
reactivation.
Results: The medical records of 80 T. cruzi–HIV co-infected patients were reviewed. The most likely route
of T. cruzi infection was vector-borne (32/80 patients), followed by intravenous drug use (12/80). Nine of
80 patients had reactivation. Patients without reactivation had a significantly higher CD4 T-cell count at
diagnosis of T. cruzi infection (144 cells/ml vs. 30 cells/ml, p = 0.026). Chagas disease serology was negative
in two of nine patients with reactivation.
Conclusions: Serological assays for T. cruzi infection may be negative in severely immunocompromised
patients. Direct parasitological techniques should be performed in the diagnosis of patients for whom
there is a suspicion of T. cruzi reactivation. HIV patients with a lower CD4 count are at higher risk of
reactivation.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Chagas disease is a zoonotic disease caused by Trypanosoma
cruzi, a flagellated protozoan. The acute phase of the infection is
typically asymptomatic or associated with mild symptoms such as
fever, malaise, swelling at the site of inoculation, and lymphade-
nopathy. Although it usually resolves spontaneously within 2–4
months, severe myocarditis or meningoencephalitis can be seen.
Following this phase, a chronic phase is established that lasts years
or throughout life. Approximately one-third of chronically infected
patients develop cardiomyopathy and/or megaesophagus/* Corresponding author at: Amenabar 2221 PB C, Buenos Aires, CP 1428,
Argentina. Tel.: 54911 67057596.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).megacolon after years or decades of infection (Cordova et al.,
2008; Lattes and Lasala, 2014).
Reactivation of Chagas disease, defined as a high level of
parasitemia in a patient with chronic Chagas disease, was initially
described in immunocompromised patients secondary to organ
transplantation or a hematological malignancy (Cantarovich et al.,
1992; Kohl et al., 1982). The first case recorded in an HIV-infected
patient was described in 1990 (Del Castillo et al., 1990). Since then,
T. cruzi–HIV co-infection has been documented in countries where
Chagas disease is endemic, as well as in non-endemic countries as
a result of the migration flow from Latin America to the rest of the
world (Almeida et al., 2011; Salvador et al., 2014, 2015). The rate of
T. cruzi–HIV co-infection ranges from an estimated 1.3% in Brazil, to
5% in endemic areas of Brazil and 7.1% in intravenous drug users in
Argentina (Dolcini et al., 2008; Stauffert et al., 2017). Chagas
disease reactivation most frequently involves the central nervousciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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(Almeida et al., 2011). Although many case reports and case series
of Chagas disease reactivation in HIV-infected patients have been
published, few articles have described T. cruzi–HIV co-infection in
patients without reactivation (Almeida et al., 2010, 2011; Sartori
et al., 1998, 2007).
The aim of this study was to describe the epidemiological and
clinical features of T. cruzi infection in HIV-infected patients and to
compare these findings between patients with and without Chagas
disease reactivation.
Patients and methods
The medical records of T. cruzi–HIV co-infected patients, who
were treated at the Francisco J. Muñiz Infectious Diseases Hospital
from January 2005 to December 2014, were reviewed retrospec-
tively.
HIV infection was diagnosed by ELISA (VIDAS HIV; bioMérieux,
France) and confirmed by Western blot tests (Bioblot HIV-1 plus;
Biokit, Spain). Chagas disease was diagnosed when the following
serological assays were positive: ELISA (ELISA Chagas III; Grupo
BiosChile Ingenierìa Genética, Chile) and indirect hemagglutina-
tion (HAI; Chagas Polychaco S.A.I.C, Argentina). If results were
discordant, a third assay was performed: indirect immunofluores-
cence assay with antigens provided by the National Parasitology
Institute “Dr. Fatala Chaben”, ARCHITECT Chagas (Abbott Labora-
tories), or the detection of trypomastigotes in fluids and/or
amastigote nests in tissue samples.
The following data were assessed: sex, nationality, age at HIV
diagnosis and at Chagas disease diagnosis, possible source of
acquisition of HIV and T. cruzi infection, time between HIV and
Chagas disease diagnosis, follow-up since Chagas disease diagno-
sis, minimum CD4 T-cell count and CD4 T-cell count at Chagas
disease diagnosis, opportunistic infections prior to or at the time of
Chagas disease diagnosis, results of direct microscopic examina-
tion for T. cruzi in blood, fluids, or tissue, Chagas disease treatment,
use of highly active antiretroviral therapy (HAART) at the time of
Chagas disease diagnosis and at the last follow-up evaluation, and
finally the mortality rate in patients with T. cruzi reactivation.
The clinical form of chronic Chagas disease was classified as
indeterminate, cardiac, and/or digestive chronic disease, accordingTable 1
Epidemiological characteristics of Trypanosoma cruzi–HIV co-infected patients.
With react
(n = 9)
Sex, male (%) 8 (88.9) 
Age at Chagas disease diagnosis, years, median (IQR) 39 (18) 
Age at HIV diagnosis, years, median (IQR) 33 (24) 
Nationality, n (%)
Argentinean 7 (77.8) 
Bolivian 0 
Chilean 0 
Paraguayan 0 
Peruvian 1 (11.1) 
Unknown 1 (11.1) 
Risk factor for HIV, n (%)
Unprotected heterosexual contact 4 (44.5) 
MSM 1 (11.1) 
IDU 2 (22.2) 
Congenital 1 (11.1) 
Unknown 1 (11.1) 
T. cruzi infection probable acquisition route, n (%)
Vector-borne 5 (55.6) 
IDU 2 (22.2) 
Vector-borne and IDU 0 
Unknown 2 (22.2) 
IQR, interquartile range; MSM, men who have sex with men; IDU, intravenous drug usto clinical, radiological, and electrocardiographic findings (Dias
et al., 2016). At least a chest X-ray and electrocardiogram were used
for classification; echocardiography and digestive tube radiogra-
phy (barium enema and/or series) were assessed when done
(Guías para la atención al paciente infectado con Trypanosoma
cruzi, 2012).
Chagas disease reactivation was defined when clinical mani-
festations of the disease, not observed in chronically infected
immunocompetent individuals, were seen, and when T. cruzi was
detected by direct microscopic examination in biological samples
of peripheral blood or other fluids (cerebrospinal fluid (CSF),
pericardial effusion, peritoneal effusion, etc.), or in those patients
with high burdens of T. cruzi amastigote nests revealed by
histopathological studies (biopsy or autopsy) (Almeida et al.,
2010). The following data were also assessed in patients with T.
cruzi reactivation: organ involvement, time to the diagnosis of
reactivation, treatment received, and outcome.
This study was approved by the Ethics Committee of the
Francisco J. Muñiz Infectious Diseases Hospital.
Continuous variables were compared between groups using the
t-test or the Mann–Whitney U-test when appropriate. Multivariate
analyses could not be done due to the small sizes of the groups.
Categorical variables were compared between groups using the
Pearson Chi-square test or Fisher’s exact test when the Chi-square
test assumptions were not fulfilled. Significance was set at p < 0.05.
Data were entered into and analyzed using IBM SPSS Statistics
software, version 23 (IBM Corp, Armonk, NY, USA).
Results
The medical records of 80 T. cruzi–HIV co-infected patients were
reviewed. Sixty-three patients were male. The median age of the
patients at Chagas disease diagnosis was 40.5 years (interquartile
range (IQR) 13 years) and at HIV diagnosis was 34.5 years (IQR 20.5
years). The most likely route of T. cruzi infection acquisition was
vector-borne transmission (32/80 patients), followed by intrave-
nous drug use (IDU). All patients were considered in the chronic
phase of Chagas disease, as they were adults living in a
metropolitan area without vector-borne transmission and were
not active IDUs. Only 25 of the 80 patients were on HAART at the
time of Chagas disease diagnosis. Patients with and withoutivation Without reactivation
(n = 71)
Total
(n = 80)
55 (77.5) 63 (78.8)
42 (13) 40.5 (13)
35 (21) 34.5 (20.5)
50 (70.4) 57 (71.4)
8 (11.3) 8 (10)
1 (1.4) 1 (1.2)
1 (1.4) 1 (1.2)
0 1 (1.2)
11 (15.5) 12 (15)
46 (64.8) 50 (62.5)
3 (4.2) 4 (5)
18 (25.4) 20 (25)
0 1(1.2)
4 (5.6) 5 (6.3)
27 (38) 32 (40)
10 (14) 12 (15)
8 (11.3) 8 (10)
26 (36.7) 28 (35)
er.
Table 2
Clinical characteristics of Trypanosoma cruzi–HIV co-infected patients.
Total
(n = 80)
Reactivation
(n = 9)
No reactivation
(n = 71)
p-Value
Minimum CD4 T-cell count, cells/ml, median (IQR) 80 (180.1) 30 (80.0) 94 (204.0) 0.032a
CD4 T-cell count at Chagas disease diagnosis, cells/ml, median (IQR) 103 (255.8) 30 (127.0) 144 (253.0) 0.026a
Patients with opportunistic infections prior/concomitant, n (%) 57 (71.3) 9 (100) 48 (68.6) 0.053
Patients on HAART at Chagas disease diagnosis, n (%) 25 (31.3%) 3 (33.3) 22 (31.0) 1.000
IQR, interquartile range; HAART, highly active antiretroviral therapy.
a Significant, p < 0.05.
Table 3
Clinical and parasitological information for patients with Chagas disease reactivation.
Patient number Tissue involvement Parasite in blood Parasite in CNS fluid Serology Treatment Outcome
23 CNS/myocardium Pos Pos Neg BZD/NFT Relapse (died following second episode)
39 CNS Neg Pos Pos BZD Died
54 CNS ND Pos Pos BZD Disease resolution
65 CNS Neg Pos Pos BZD Died
70 CNS Neg Pos Pos BZD Died
73 CNS Neg Pos Pos None Died
78 CNS Neg Pos Neg BZD Disease resolution
79 CNS Neg Pos Pos BZD Disease resolution
80 CNS/myocardium ND Pos Pos BZD Died
CNS, central nervous system; Neg, negative; Pos, positive; ND, not done; BZD, benznidazole; NFT, nifurtimox.
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Nine patients had confirmed reactivation of Chagas, with one of
these patients experiencing two episodes of reactivation. Clinical
data related to Chagas disease in the 71 patients without
reactivation were complete in only 35 cases. In these 35 cases,
the clinical form was indeterminate for 28 and cardiac for seven;
no digestive form of infection was observed.
Patients without reactivation had a significantly higher CD4 T-
cell count at diagnosis of T. cruzi infection (144 cells/ml vs. 30 cells/
ml, Mann–Whitney U-test p = 0.026) and higher minimum CD4 T-
cell count (94 cells/ml vs. 30 cells/ml, Mann–Whitney U-test
p = 0.032) than patients with reactivation. Furthermore, fewer
patients without reactivation had opportunistic diseases prior to or
at the time of Chagas disease diagnosis than patients with
reactivation, although the difference was not significant (68.6% vs.
100%, Fisher’s exact test p = 0.053) (Table 2).
Chagas disease reactivation involved the CNS alone in seven
patients, while CNS and the heart were affected simultaneously in
two patients. Trypomastigotes were observed in the CSF samples of
all patients (n = 9), while parasitemia was studied in seven patients
and was positive in only one of them. Trypomastigotes were also
isolated from the pericardial effusion of one patient. Chagas
disease serology was negative by multiple techniques on numer-
ous samples from two of the nine patients with reactivation. With
the exception of the one patient who died before starting
treatment, all patients received benznidazole; one patient was
switched to nifurtimox due to toxicity. T. cruzi reactivation was
considered the cause of death for six of the nine patients with
reactivation (Table 3).
Discussion
The present study appears to represent the largest case series of
HIV and T. cruzi co-infection published to date. Although the
vector-borne route of infection was the most frequent, a significant
number of these patients could have been infected with T. cruzi
through IDU, as has been described previously (Dolcini et al., 2008;
Scapellato et al., 2006). Chagas disease should be assessed in HIV-
positive patients who have been engaged in IDU, regardless of their
or their mothers’ birthplace or place of residence.Current HIV guidelines from the Argentinean Ministry of Health
recommend assessing Chagas disease serology in all HIV-positive
patients and performing a cardiac examination annually if T. cruzi
infection is confirmed (Benetucci et al., 2013; Guías para la
atención al paciente infectado con Trypanosoma cruzi, 2012). It is
noteworthy that the median time from HIV diagnosis to the
diagnosis of T. cruzi infection was prolonged (median 5.5 years, IQR
11.74 years).
Serological testing for Chagas disease was negative in two
patients (2.5%), both with reactivation, who were diagnosed by the
detection of T. cruzi in CSF samples. Non-reactive serological tests
for T. cruzi infection in severely immunocompromised HIV-positive
patients have been described previously (Cordova et al., 2008;
Almeida et al., 2011). Therefore, the diagnosis of T. cruzi infection
should not be rejected in immunocompromised patients with risk
factors for Chagas disease, especially when there is a high
suspicion that reactivation might have occurred.
There were nine patients with reactivation in this series
(11.25%). When compared to patients without reactivation, they
appeared more severely immunocompromised. Lower CD4 T-cell
counts have already been described in HIV patients with T. cruzi
reactivation (Almeida et al., 2011). No differences with previous
reports were observed regarding the clinical presentation of T. cruzi
reactivation (Almeida et al., 2010, 2011; Cordova et al., 2008;
Simioli et al., 2017). CNS involvement was the most frequent
clinical form of reactivation, presenting as meningoencephalitis,
with (seven patients) or without (two patients) cerebral mass
lesions seen on neuroimaging by computed tomography scan or
magnetic resonance imaging, followed by cardiac involvement in
two of the nine patients (these two patients also had CNS
involvement). Although all patients were treated in an infectious
diseases hospital with expertise in the management of HIV and
Chagas disease, T. cruzi reactivation had a high mortality rate of
66.7%.
As a result of the retrospective design of this study, certain data
were incomplete, such as family history of Chagas disease and
myocardial involvement.
In conclusion, Chagas disease reactivation is an AIDS-defining
illness with a high mortality rate. HIV-infected people should be
studied routinely for Chagas disease. Serological assay results may
A.G. Benchetrit et al. / International Journal of Infectious Diseases 67 (2018) 118–121 121be negative in severely immunocompromised patients. Therefore,
direct parasitological techniques should be performed in all
patients for whom there is a clinical suspicion of T. cruzi
reactivation, especially if they have a significant epidemiological
background or IDU history. HIV-infected patients with lower CD4
counts are at higher risk of reactivation. HAART is mandatory for
co-infected T. cruzi and HIV patients.
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